Alsatinib 100mg Tablet 30s

Introduction to Alsatinib 100mg Tablet 30s

Alsatinib 100mg Tablet 30s is a medication primarily used to treat certain types of cancer, specifically leukemia. This tablet form of Alsatinib is designed to manage conditions like chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), which affect the blood and bone marrow.

Composition of Alsatinib 100mg Tablet 30s

Alsatinib 100mg Tablet 30s contains the active ingredient Dasatinib, which is a tyrosine kinase inhibitor. This component works by blocking specific proteins that promote the growth of cancer cells, thereby slowing down or stopping their proliferation.

Uses of Alsatinib 100mg Tablet 30s

• Treatment of chronic myeloid leukemia (CML)
• Treatment of acute lymphoblastic leukemia (ALL)

Side effects of Alsatinib 100mg Tablet 30s

• Common side effects: Low blood cell counts, increased risk of infection, fluid retention causing swelling
• Serious side effects: Severe allergic reactions, liver problems, heart issues

Precautions of Alsatinib 100mg Tablet 30s

Alsatinib 100mg Tablet 30s should not be used by individuals allergic to Dasatinib or those with severe liver problems. Regular monitoring is essential due to potential fluid retention and heart-related issues.

How to Take Alsatinib 100mg Tablet 30s

The usual starting dose for adults is 100 mg once daily. It is taken as a tablet, with or without food, but should not be consumed with grapefruit. Always follow your doctor's instructions regarding dosage and administration.

Conclusion of Alsatinib 100mg Tablet 30s

Alsatinib 100mg Tablet 30s, containing the active ingredient Dasatinib, belongs to the therapeutic class of tyrosine kinase inhibitors. It is primarily used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Manufactured for effective cancer management, this medication requires careful adherence to prescribed guidelines and regular monitoring due to potential side effects. Alsatinib 100mg Tablet 30s is a critical component in the treatment of specific leukemia types, offering hope for improved patient outcomes.